But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially facing generic competition, there’s a lot to play for ...

She prescribed Restasis, but my condition didn’t improve after three months of use. She then switched me to Xiidra and instructed me to use it for two more refills, which lasted nine months.

But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially facing generic competition, there’s a lot to play for ...